Zacks Research Forecasts Alkermes’ Q1 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of Alkermes in a research report issued on Wednesday, April 9th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.28 for the quarter, down from their previous estimate of $0.29. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q2 2025 earnings at $0.34 EPS, FY2025 earnings at $1.33 EPS, Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.43 EPS, FY2026 earnings at $1.24 EPS and FY2027 earnings at $1.14 EPS.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

A number of other equities analysts also recently commented on the company. Royal Bank of Canada started coverage on Alkermes in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 target price for the company. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and raised their target price for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. HC Wainwright restated a “neutral” rating and set a $46.00 price target on shares of Alkermes in a research report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Alkermes Stock Up 2.0 %

Shares of NASDAQ:ALKS opened at $27.54 on Monday. The company has a market cap of $4.54 billion, a PE ratio of 12.69, a P/E/G ratio of 2.20 and a beta of 0.39. Alkermes has a fifty-two week low of $22.90 and a fifty-two week high of $36.45. The firm has a 50-day simple moving average of $33.06 and a 200 day simple moving average of $30.47.

Institutional Investors Weigh In On Alkermes

Several hedge funds and other institutional investors have recently bought and sold shares of ALKS. Avoro Capital Advisors LLC bought a new stake in Alkermes during the fourth quarter worth approximately $70,462,000. Norges Bank purchased a new position in Alkermes during the 4th quarter worth approximately $56,684,000. RTW Investments LP raised its position in Alkermes by 13.6% during the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock valued at $217,363,000 after buying an additional 903,802 shares during the period. Nuveen Asset Management LLC grew its stake in Alkermes by 109.5% during the 4th quarter. Nuveen Asset Management LLC now owns 1,659,821 shares of the company’s stock valued at $47,736,000 after acquiring an additional 867,492 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Alkermes by 147.4% in the 4th quarter. JPMorgan Chase & Co. now owns 889,472 shares of the company’s stock valued at $25,581,000 after purchasing an additional 529,962 shares during the period. 95.21% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Alkermes

In other news, EVP Craig C. Hopkinson sold 100,918 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total value of $3,234,421.90. Following the completion of the sale, the executive vice president now owns 44,290 shares in the company, valued at $1,419,494.50. This represents a 69.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 4.89% of the stock is currently owned by corporate insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.